Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 761-766

  Lin, Qiang ^a   Meng, Fan Jie ^a   Liu, Yue'e ^a   Wang, Na ^a   Ren, Xiao Cang ^a   Chen, Xue Ji ^a   Ge, Xiao Hui ^b   Liu, Chao Xing ^c   Hu, Jing ^a   Wang, Dong Ying ^a   Cao, Bin ^a   Zhao, Yannan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Capecitabine; Chemotherapy; Docetaxel; Non small cell lung cancer; Second line therapy

Indexed keywords

CAPECITABINE; DOCETAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84863182524     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.575     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
4. Comer AM and Goa KL: Docetaxel: a review of its use in non-small cell lung cancer. Drugs Aging 17: 53-80, 2000.
5. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
6. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
7. Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R and Villalona-Calero MA: Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 11: 1870-1876, 2005.
8. Lee JJ, Han JY, Lee DH, Kim HY, Chun JH, Lee HG, Yoon SM, Lee SY and Lee JS: A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. Jpn J Clin Oncol 36: 761-767, 2006.
9. Liu ZH, Liao XL, Zhou WX, Li YQ, Lu YK, Tan XH, Xie WM and Hu XH: Phase II trial of docetaxel combined with fluoropyrimidines as the second line therapy for patients with non-small cell lung cancer. Acta Medicine of GuangXi Medical University 25: 706-708, 2008 (In Chinese).
10. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P and Quoix E: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16: 90-96, 2005.
11. Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ, Chen YM and Perng RP: Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 35: 700-706, 2005.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
13. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999.
14. Davies AM, Lara PN Jr, Mack PC and Gandara DR: Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother 4: 553-565, 2003.
15. Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, Koumpou M, Mylonakis N, Xiros N, Economopoulos T and Raptis SA: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16: 294-299, 2005.
16. Zhang YF, Yu YF and Lu S: Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer. Natl Med J China 89: 1544-1548, 2009 (In Chinese).
17. Gu LP, Shen SP and Chen ZW: Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer. Chin J Oncol 32: 939-942, 2010 (In Chinese).
18. Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takada Y, et al: Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20: 835-841, 2009.
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oralfluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
20. Liu SL, Gu SX, Shen SJ, Tao YH and Jing C: Effect of weekly administration of docetaxel combined with oxaliplatin as second-line therapy on non-small cell lung cancer. Chin Clin Oncol 15: 749-751, 2010 (In Chinese).
21. Liu Y and Cheng Y: The clinical study of weekly docetaxel and cisplatin as a second-line therapy for recurrent or progressive non-small cell lung cancer. Oncol Progress 6: 528-531, 2008 (In Chinese).